Pandemic Highlights Critical Role of Technology-Driven Glycemic Management as Glytec Propels Customer Base Past 300 Healthcare Facilities

Feb. 9, 2021 14:00 UTC

Nationally-Recognized Research and the Imperative for Health Systems to Free Beds and Improve Outcomes More Quickly Fuel Insulin Dosing Technology Company’s Growth

WALTHAM, Mass.--(BUSINESS WIRE)-- Glytec, the only provider of insulin management software across the continuum of care, today announced that health systems significantly expanded use of its eGlycemic Management System® (eGMS) in 2020 to improve care, cost and outcomes through personalized insulin treatment recommendations. Over the past 12 months, Glytec’s FDA-cleared eGMS software was contracted for use in an additional 6,500 beds and the company is now partnering with over 300 healthcare facilities across the country.

In addition, Glytec leveraged its clinical expertise and data from its large install base over the past year to conduct and publish research about the impact of glycemic management on COVID-19 mortality and outcomes. The company’s two studies, published in peer-reviewed journals, contributed to the growing understanding providers have about the importance of glycemic management and the knowledge that is driving demand for Glytec’s eGMS.

“Our strong growth in 2020, our fourteenth year in business, is a testament to the real value Glytec delivers. It’s especially significant that we’ve achieved this growth during the COVID-19 pandemic and speaks to the awakening many providers are having around the importance of glycemic management,” said Ed Furlong, President and CEO of Glytec. “More than a third of hospitalized patients require insulin treatment during their stay, regardless of a diabetes diagnosis, and healthcare organizations are realizing the role electronic support systems play in improving outcomes and controlling costs. This groundswell was occurring before the pandemic, and will continue afterwards, but COVID-19 helped shine a light on the impact eGMS can have on such a large population.”

In the past 12 months, Glytec increased the number of beds covered nationwide by its eGMS software by 25%. This increase was driven by both new customers and contract expansions at health systems already using Glytec’s eGMS. Some of these health systems include Kettering Health Network, Sarasota Memorial Health Care System, CoxHealth, West Tennessee Healthcare, Tift Regional Health System and Garnet Health.

“Glytec has played an important role making sure patients in need of glycemic management during their stay get the best care possible. That’s why we recently expanded use of Glytec at our flagship hospital, and plan to introduce it at other facilities in our system,” said Mollie Taylor, Executive Director of Intensive Care Units and Progressive Care Units at West Tennessee Healthcare. “eGlycemic Management has empowered our caregivers. eGMS improves speed and efficiency compared to the manual insulin titration regimens that most facilities still use, and more importantly, eGMS helps get patients’ blood glucose into range more quickly, which improves outcomes and lowers length of stay.”

Strengthening its efforts to provide both technology and expertise to the 300-plus hospitals using Glytec, the company introduced a number of initiatives over the past year to help providers improve COVID-19 patient outcomes as a result of enhanced glycemic management. This included the formation of the “COVID Collaborative,” which enabled health system leaders to share knowledge about COVID response and treatment options, and the creation of a curated COVID-19 resource hub.

Glytec also leveraged the broad reach of its customer footprint, national database of patient records and clinical expertise to spearhead research efforts that found and measured dramatically worse outcomes for hospitalized COVID-19 patients with uncontrolled hyperglycemia. The first study, published by the Journal of Diabetes Science and Technology in April, concluded that patients suffering from hyperglycemia without a pre-existing diabetes diagnosis exhibited a mortality rate seven times greater than patients that remained in normal glycemic ranges. A second study, published in December by Diabetes Care, a journal of the American Diabetes Association, was the first to measure the window of opportunity for treating COVID-19 patients with hyperglycemia or diabetes on admission. The study revealed a sevenfold mortality risk for non-ICU patients with severe hyperglycemia after 48 to 72 hours and strongly suggested early glycemic intervention would reduce mortality rates in COVID-19 patients.

Glytec’s eGMS tracks and analyzes glycemic data, enabling early identification of hyperglycemic patients, efficient and effective intervention and ongoing optimization of care. Glytec’s FDA-cleared insulin titration software, Glucommander™, is the foundation of its electronic Glycemic Management System. Glucommander provides personalized insulin dosing guidance, driven by evidence-based proprietary algorithms, to help caregivers quickly optimize insulin therapy and manage glucose levels to a prescribed target range. The software is proven to deliver reductions in hypoglycemia by 99.8%, 30-day readmissions by 36-68% and length of stay by up to 3.2 days. The safety and efficacy of Glytec’s eGMS has been validated in more than 80 research studies to date.

To learn more about Glytec and the impact that insulin management software can have on health systems, visit www.glytecsystems.com.

About Glytec

Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) or LinkedIn, or visit www.GlytecSystems.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005231/en/

Contacts

Geoff Lopes
fama PR for Glytec
617-986-5038
Glytec@famapr.com

Source: Glytec

Back to news